How much does serpatinib (serpatinib) cost when included in medical insurance?

Selpercatinib (Selpercatinib) is a targeted therapy used to treat certain types of cancers with RET gene fusions or mutations. Its efficacy is remarkable, but its price is high, which puts considerable financial pressure on patients. Inclusion in medical insurance is crucial to reducing the financial burden on patients. However, as of now, Serpatinib has not been included in China's medical insurance list, so patients need to purchase it at their own expense.

If Serpatinib is included in medical insurance, the price will drop significantly. The specific price may vary due to different medical insurance reimbursement ratios and policies. Generally speaking, after a drug is included in medical insurance, the reimbursement ratio is usually between 50% and 90%. The specific ratio depends on the local medical insurance policy and the patient's medical insurance type.

Assuming that the reimbursement ratio of Serpatinib after being included in medical insurance is 70% based on the current domestic market price of more than 10,000 yuan per bottle, the actual cost paid by patients will be significantly reduced. In addition, after being included in medical insurance, the drug purchase process for patients will be more standardized and convenient. Drugs in the medical insurance catalog are usually sold in regular hospitals and pharmacies, and patients can be reimbursed through the medical insurance system, reducing uncertainty and risks in the drug purchase process. At the same time, the review and supervision of the medical insurance catalog can also ensure the quality of drugs and the stability of the supply chain, and ensure the safety of patients' medication.

However, the process of including drugs in medical insurance requires strict review and negotiation. Pharmaceutical companies need to negotiate prices with the National Medical Insurance Administration to determine reasonable medical insurance payment standards. After being included in medical insurance, drug prices will be subject to certain restrictions, which is also one of the factors that pharmaceutical companies need to consider. Therefore, the specific price and reimbursement ratio after inclusion in medical insurance still need to wait for the official announcement from relevant departments.

In general,Seputinib (Selpatinib) once included in medical insurance, will greatly reduce the financial burden on patients and improve the accessibility and utilization of the drug. Patients no longer need to purchase drugs at their own expense, which will greatly reduce the medical burden. It will also help regulate the drug market and ensure drug quality and supply chain stability. It is hoped that as the medical insurance system continues to improve, more innovative drugs like Serpatinib will be included in medical insurance as soon as possible to benefit more patients.